Story perspectives

Daraxonrasib Nears U.S. Approval, Extends Pancreatic Cancer Survival

5/12/2026

Summary

Story summary

Daraxonrasib is nearing U.S. regulatory approval as the first drug to extend pancreatic-cancer patients’ lives.
The drug targets the KRAS protein that drives all pancreatic tumors and many lung and colon cancers.
Scientists say the treatment could become the significant cancer-treatment advance in the past 15 years since immunotherapy.
Its development succeeded after decades of false starts using public-private research funding, with researcher Adrienne Cox noting advance overturns previous dogma.

1 of 1

Story summary

Daraxonrasib is nearing U.S. regulatory approval as the first drug to extend pancreatic-cancer patients’ lives.
The drug targets the KRAS protein that drives all pancreatic tumors and many lung and colon cancers.
Scientists say the treatment could become the significant cancer-treatment advance in the past 15 years since immunotherapy.
Its development succeeded after decades of false starts using public-private research funding, with researcher Adrienne Cox noting advance overturns previous dogma.